Roger Adsett Joins Definium As Commercial Focus Meets Trial Milestones [Yahoo! Finance]
Definium Therapeutics, Inc. - Common Shares (DFTX)
Company Research
Source: Yahoo! Finance
Definium Therapeutics (NasdaqGS:DFTX) has appointed biopharma veteran Roger Adsett to its Board of Directors. Adsett brings extensive experience in global drug launches and commercial leadership. The appointment comes as Definium prepares for key late stage trial milestones and potential product launches. For investors watching Definium Therapeutics at a share price of $16.88, this board change comes after very large 3 year gains and a 148.6% return over the past year. The stock is also up 23.8% year to date and 26.1% over the past month, even with a 3% decline over the past week. That mix of longer term performance and recent volatility forms the backdrop for a company moving into a more commercially focused phase. The arrival of a commercial operator like Adsett indicates that Definium is preparing for the practical realities of moving from late stage trials into potential product launches. As Phase 3 readouts approach, investors will likely focus on how the company aligns
Show less
Read more
Impact Snapshot
Event Time:
DFTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DFTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DFTX alerts
High impacting Definium Therapeutics, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
DFTX
News
- Definium Therapeutics (DFTX) had its price target raised by HC Wainwright from $55.00 to $70.00. They now have a "buy" rating on the stock.MarketBeat
- Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Reports Full-Year 2025 Financial Results and Business UpdatesBusiness Wire
DFTX
Earnings
- 2/26/26 - Miss
DFTX
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- DFTX's page on the SEC website